Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

142
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
142
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

74
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

1.7K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.7K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

122
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
122
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

4.9K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pilot study of magnetic resonance fingerprinting and radiomics analysis in autosomal dominant polycystic kidney disease.

Kidney international·2026
Same author

Pregnancy and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Journal of the American Society of Nephrology : JASN·2026
Same author

Future needs for clinical trials in autosomal dominant polycystic kidney disease.

Nature reviews. Nephrology·2026
Same author

Relationship between Total Kidney Volume and eGFR in Autosomal Dominant Polycystic Kidney Disease.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Impact of Area-Level Socioeconomic Deprivation on Post-PCI Outcomes Stratified by P2Y<sub>12</sub> Inhibitor Therapy.

JACC. Advances·2026
Same author

Development and Validation of a Multivariable Prediction Model for Kidney Failure in Early Autosomal Dominant Polycystic Kidney Disease.

Journal of the American Society of Nephrology : JASN·2026

Related Experiment Video

Updated: Apr 21, 2026

Assessing Murine Resistance Artery Function Using Pressure Myography
07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

23.5K

Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension.

Vanessa Fontana1, Caitrin W McDonough2, Yan Gong2

  • 1Department of Pharmacology, Faculty of Medical Sciences, University of Campinas, Campinas, SP, Brazil (V.F.).

Journal of the American Heart Association
|November 12, 2014
PubMed
Summary

A specific gene variant, ATP2B1 rs12817819, is linked to a higher risk of resistant hypertension (RHTN). This finding may help identify individuals with coronary artery disease at greater risk for uncontrolled blood pressure.

Keywords:
geneticshypertensionpharmacologyresistant hypertension

More Related Videos

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta
08:08

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta

Published on: June 10, 2015

12.0K
Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.9K

Related Experiment Videos

Last Updated: Apr 21, 2026

Assessing Murine Resistance Artery Function Using Pressure Myography
07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

23.5K
Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta
08:08

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta

Published on: June 10, 2015

12.0K
Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.9K

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Pharmacogenomics

Background:

  • Resistant hypertension (RHTN) significantly elevates cardiovascular risk.
  • Limited data exists on genetic factors contributing to RHTN.
  • Understanding genetic predispositions is crucial for managing RHTN.

Purpose of the Study:

  • To identify genetic variants associated with RHTN in patients with coronary artery disease (CAD).
  • To investigate the functional impact of identified genetic polymorphisms on gene expression.

Main Methods:

  • Utilized a gene-centric array of approximately 50,000 single-nucleotide polymorphisms (SNPs).
  • Conducted logistic regression analysis in European American and Hispanic participants from the INVEST-GENES study.
  • Performed replication analysis in the WISE study and measured mRNA expression for functional investigation.

Main Results:

  • The ATP2B1 rs12817819 polymorphism was significantly associated with RHTN in both European American and Hispanic cohorts.
  • A meta-analysis combining INVEST and WISE data showed chip-wide significance for rs12817819.
  • Expression analyses confirmed significant differences in ATP2B1 mRNA levels based on rs12817819 genotype.

Conclusions:

  • The A allele of ATP2B1 rs12817819 is associated with an increased risk of RHTN.
  • This genetic marker may be relevant for hypertensive individuals with documented CAD or suspected ischemic heart disease.